MOG and myelitis: These profiles included the serum titer levels of the disease-specific antibodies (AQP4-IgG and MOG-IgG), clinical phenotype of the neurological episode at the time of the blood test (optic neuritis, brain lesions, or myelitis), neurological disability level 1 year after the neurological episode in the blood test, and the presence of clinical relapses in the first 2 years after the neurological episode.